跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 870 条关于
“177Lu-RAD202”
全部
870
临床试验
563
药物
217
机构
0
资讯
90
去年
Radiopharm Theranostics' RAD 202 Receives Ethics Approval for Phase 1 Trial in HER2-Expressing Solid Tumors
去年
Radiopharm Theranostics Advances Phase 1 Trial of PD-L1 Targeting Radiotherapeutic for Advanced Cancers
2年前
177Lu-PNT2002 Demonstrates Promising Phase 3 Outcomes in Metastatic Castration-Resistant Prostate Cancer
去年
Lutetium-177 Dotatate Shows Promise in Refractory Meningioma
4年前
Phase 1/2 Trial Investigates 225Ac-J591 and 177Lu-PSMA-I&T Combination in Metastatic Castration-Resistant Prostate Cancer
去年
177Lu-PSMA-I&T Demonstrates rPFS Benefit in mCRPC Patients in ECLIPSE Trial
去年
DMC Approves Dose Escalation in Spago Nanomedical's 177Lu-SN201 Cancer Trial
去年
NETTER-2 Trial: 177Lu-Dotatate Shows Promise but Raises Questions in High-Grade NETs
11个月前
Spago Nanomedical's 177Lu-SN201 Shows Promising Tumor Uptake in Phase I/IIa Trial
10个月前
FDA Accepts ITM's New Drug Application for 177Lu-edotreotide in Gastroenteropancreatic Neuroendocrine Tumors
第 1 页,共 9 页
上一页
下一页